NCT02646137.

Study name	Single session combined locoregional therapies for hepatocellular carcinoma
Methods	Allocation: Randomised Intervention model: Parallel assignment Masking: None (open‐label)
Participants	Inclusion Criteria: Child classification A or B Serum albumin ≥ 3 gm/L Serum bilirubin < 2.5 mg/dL Platelet count ≥ 70,000 mm3 INR ≤ 1.6 Serum creatinine < 2 mg/dL Tumour size more than 4 cm and confined to one lobe of the liver Exclusion Criteria: Patients with portal vein thrombosis A technically inaccessible hepatic artery Metastatic HCC More than three lesions Lesions in close proximity to the portal vein, inferior vena cava, or gallbladder were excluded from the study.
Interventions	(1) Active comparator: Transarterial chemoembolisation (TACE) (2) Experimental: Radiofrequency ablation with TACE (3) Experimental: Microwave ablation combined with TACE
Outcomes	Number of patients with successful ablation [time frame: 3 months]
Starting date	January 2015
Contact information	Sherief Abd‐Elsalam 00201000040794, mailto:Sherif_tropical%40yahoo.com?subject=NCT02646137, Combined TACE and RF, Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
Notes	None

AASLD: American Association for the Study of Liver Diseases
AFP: alpha foetoprotein
ALB: albumin
ALT: alanine aminotransferase
AST: aspartate transaminase
BCLC B: Barcelona Clinic Liver Cancer Stage B (Intermediate Stage)
BUN: blood area nitrogen
CORTT: abbreviation in study name not written out anywhere in the text record
CT: computer tomography
EASL: European Association for the Study of the Liver
ECOG: Eastern Cooperative Oncology Group
HBsAg: hepatitis B surface antigen
HCC: hepatocellular carcinoma
INR: international normalised ratio
IVC: inferior vena cava
MRI: magnetic resonance imaging
MWA: microwave ablation
PT: prothrombin time
PV: portal vein
PVTT: portal vein tumour thrombosis
RFA: radiofrequency ablation
TACE: transarterial chemoembolisation